Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

Completed · Phase 2

Conditions studied: Hormone-Refractory Prostate Cancer

In brief

Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.

Key facts

Study ID

NCT00151073

Run by

University of Michigan Rogel Cancer Center

People needed

28

Starts

2002-04-01

Expected to finish

2007-09-01

Last updated by the study team

2015-01-22

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• The University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.